logo
Us health officials crack down on kratom-related products after complaints from supplement industry

Us health officials crack down on kratom-related products after complaints from supplement industry

Al Arabiya29-07-2025
US health officials are warning Americans about the risks of an opioid-like ingredient increasingly added to energy drinks, gummies, and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical known as 7-hydroxymitragynine is a component of kratom, a plant native to Southeast Asia that has gained popularity in the US as an unapproved treatment for pain, anxiety, and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying them as dangerously strong synthetic versions of the original ingredient.
The FDA action is not focused on natural kratom leaf products, according to a statement Tuesday by the US Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of 7-OH and its distinction from the kratom plant leaf. Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which also includes LSD and heroin.
'7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs, including prescription medicines and illicit substances.
Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury, and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies, and powders infused with the drug. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions including pain, arthritis, and anxiety.
Supplement executives quickly applauded the move. 'The FDA demonstrated the exact kind of data-driven proactive regulatory excellence needed to safeguard unwitting consumers across the US,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements.
Nearly a decade ago, the federal government came close to a national ban on the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1 of illegal drugs. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl.
Since then, FDA regulators have continued to issue warnings about cases of injury, addiction, and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA vaccine chief leaving agency after less than three months
FDA vaccine chief leaving agency after less than three months

Al Arabiya

time6 days ago

  • Al Arabiya

FDA vaccine chief leaving agency after less than three months

The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech companies, patient groups, and conservative allies of President Donald Trump. Dr. Vinay Prasad did not want to be a distraction and was stepping down from his role as the FDA's top vaccine regulator to spend more time with his family, a spokesperson for the Department of Health and Human Services said in a statement late Tuesday. Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Prasad joined the FDA in May after years as an academic researcher at the University of California, San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. But in recent weeks, Prasad became a target of conservative activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchennes muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term, he signed the 'Right to Try' law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a steep rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA, which included overseeing the approval of the first COVID vaccines and therapies.

Us health officials crack down on kratom-related products after complaints from supplement industry
Us health officials crack down on kratom-related products after complaints from supplement industry

Al Arabiya

time29-07-2025

  • Al Arabiya

Us health officials crack down on kratom-related products after complaints from supplement industry

US health officials are warning Americans about the risks of an opioid-like ingredient increasingly added to energy drinks, gummies, and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical known as 7-hydroxymitragynine is a component of kratom, a plant native to Southeast Asia that has gained popularity in the US as an unapproved treatment for pain, anxiety, and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying them as dangerously strong synthetic versions of the original ingredient. The FDA action is not focused on natural kratom leaf products, according to a statement Tuesday by the US Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of 7-OH and its distinction from the kratom plant leaf. Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which also includes LSD and heroin. '7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs, including prescription medicines and illicit substances. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury, and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies, and powders infused with the drug. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions including pain, arthritis, and anxiety. Supplement executives quickly applauded the move. 'The FDA demonstrated the exact kind of data-driven proactive regulatory excellence needed to safeguard unwitting consumers across the US,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements. Nearly a decade ago, the federal government came close to a national ban on the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1 of illegal drugs. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction, and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Sarepta will resume gene therapy shipments after fda review of recent patient death
Sarepta will resume gene therapy shipments after fda review of recent patient death

Al Arabiya

time28-07-2025

  • Al Arabiya

Sarepta will resume gene therapy shipments after fda review of recent patient death

Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchennes muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company shares surged more than 16 percent after the announcement to 13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product. Elevidys is the first gene therapy approved in the US for Duchennes muscular dystrophy–the fatal muscle-wasting disease that affects boys and young men resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients including those who can no longer walk. The FDA decision Monday significantly improves Elevidys' sales outlook in the near-term, Jefferies analyst Andrew Tsai told investors in a note after the announcement. 'The street will feel relieved about the situation suggesting meaningful stock upside potential.' Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury–a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy. FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients. 'The FDA will continue to work with the sponsor regarding non-ambulatory patients which remains subject to a voluntary hold following two deaths,' FDA said in its statement.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store